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Abstract
The E4 allele of the ApoE gene has consistently been shown to be related to an increased risk of Alzheimer’s disease (AD).
The E4 allele is also associated with functional and structural grey matter (GM) changes in healthy young, middle-aged and
older subjects. Here, we assess volumes of deep grey matter structures of 22 healthy younger ApoE4 carriers and 22 non-
carriers (20–38 years). Volumes of the nucleus accumbens, amygdala, caudate nucleus, hippocampus, pallidum, putamen,
thalamus and brain stem were calculated by FMRIB’s Integrated Registration and Segmentation Tool (FIRST) algorithm. A
significant drop in volume was found in the right hippocampus of ApoE4 carriers (ApoE4+) relative to non-carriers
(ApoE42), while there was a borderline significant decrease in the volume of the left hippocampus of ApoE4 carriers. The
volumes of no other structures were found to be significantly affected by genotype. Atrophy has been found to be a
sensitive marker of neurodegenerative changes, and our results show that within a healthy young population, the presence
of the ApoE4+ carrier gene leads to volume reduction in a structure that is vitally important for memory formation. Our
results suggest that the hippocampus may be particularly vulnerable to further degeneration in ApoE4 carriers as they enter
middle and old age. Although volume reductions were noted bilaterally in the hippocampus, atrophy was more
pronounced in the right hippocampus. This finding relates to previous work which has noted a compensatory increase in
right hemisphere activity in ApoE4 carriers in response to preclinical declines in memory function. Possession of the ApoE4
allele may lead to greater predilection for right hemisphere atrophy even in healthy young subjects in their twenties.
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Introduction
Apolipoprotein E (ApoE) plays a key role in neuronal
development with signalling through ApoE receptors and proteins
mediating processes including synaptic plasticity, neuronal survival
and neurite outgrowth [1,2]. ApoE also plays an important role in
lipolysis [3] and the regulation of lipid transport [4]. There are
three allelic variants of the ApoE gene in humans (E2, E3, E4) [5]
with the E4 allele consistently being shown to confer a higher risk
of developing both early and late onset Alzheimer’s disease (AD)
[6,7]. Brain structure and function have been found to be altered
in ApoE4 carriers, both in AD patients [8,9] and in healthy
subjects [10–14]. Studies have found greater rates of temporal lobe
atrophy in AD patients with greater load of E4 allele [8,9,15,16] as
well as reduced medial temporal lobe volumes in healthy ApoE4
carriers across the age spectrum [14,17–20]. However, a number
of studies have also failed to replicate these findings [21–23].
Functional studies have reported both increased [7,17,24] and
decreased [25,26] task-related BOLD signals in carrier groups
relative to non-carriers.
Specifically within younger cohorts some studies suggest that
neuronal deficits related to the E4 carrier genotype may lead to
greater recruitment of functional activation in order to reach the
same level of cognitive performance as E4 non-carriers [27–29].
Other studies have failed to find cognitive differences by ApoE
genotype in younger subjects [30], while still more studies have
found evidence for beneficial effects of the E4 carrier genotype in
young people [26,31]. Potential cognitive benefits of the ApoE4
genotype is linked with the concept of antagonistic pleiotropy
whereby E4 carriers are suggested to have cognitive advantages in
early life, which is followed by increased risk of cognitive damage
and reduced neuronal efficiency only in later life [32,33].
Much less work has been done in terms of studying how ApoE
genotype influences the structure of the healthy young brain. In
older subjects, hippocampal volume has been found to decrease
progressively from non-demented older subjects to MCI to AD,
with the additional caveat that E4 carriers within each group
exhibit significantly smaller hippocampal volumes compared to
non-carriers [34]. This also relates to earlier work that noted
reduced hippocampal volume and cortical thickness in E4 carriers
in healthy middle aged and healthy older people [20,25,35]. In
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children and young adolescents, thickness of the entorhinal cortex
has also been linked to ApoE4 carrier status [19]. However, not all
studies have found hippocampal volume to be reduced in E4
carriers [26].
Interestingly, a meta-analysis of 82 studies found that right
hippocampal volume is larger than the left in healthy adults [36].
Decreased hippocampal asymmetry [37] and diminished right
hippocampal volume have been noted in healthy elderly subjects
that were carriers of the E4 allele [38]. It has also been suggested
that changes in ‘‘normal’’ asymmetry may be a potential indicator
of early pathology [37,39–41].
The aim of the current study was to investigate the effect of
APOE genotype on deep grey matter (GM) structures in healthy
young people. FMRIB’s Integrated Registration and Segmenta-
tion Tool (FIRST) [42] was applied to detect significant differences
that may be present between the groups. To the best of our
knowledge, no work to date has quantified volumetric differences
in deep GM structures between healthy young E4 carriers and
non-carriers. Here FIRST is used to segment 15 deep GM
structures in a semi-automated manner. The primary research
question that was addressed was whether or not ApoE genotype
affects the volume of deep GM structures in healthy young people.
Methods
Ethics Statement
The study was approved by the Ethics Committee of Goethe
University and was in accordance with the Declaration of
Helsinki. All participants provided informed written consent.
Participants
44 cognitively intact persons between 20 and 38 years of age
(mean = 26.8, S.D = 4.6), all without any history of neurological or
psychiatric disease were assessed in the current study. These 44
subjects were drawn from a larger cohort of 96 subjects. All of the
44 selected subjects were right-handed, as assessed with the
Edinburgh Handedness Inventory [43] and provided written
informed consent. Ethics approval was obtained from the local
ethics committee of JWG University Frankfurt. All subjects
underwent neuropsychological assessment. Verbal learning and
memory was assessed using the German Version of the California
Verbal Learning Test (CVLT) [44,45], visual memory was tested
with the Brief Visual Memory Test - R (BVMT R) [46].
Additionally, measures of working memory and attention were
obtained using the Letter Number Sequencing (LNS) [47], Spatial
Span of the Wechsler Memory Scale 3 (WMS SS) [48] and Trail
Making Test A (TMT). The verbal IQ was tested with a German
verbal intelligence test (Mehrfachwahl-Wortschatz-Test B;
MWTB), in which subjects had to indicate real words within lists
of pseudo-words [49]. Depressive Symptoms were measured with
the German Version of the Beck Depression Inventory (BDI 2)
[50,51].
All participants from the larger cohort (n = 96) underwent
APOE genotyping using PCR and sequencing. For the current
analysis, 21 subjects who were heterozygote for ApoE4 (e3/e4)
and one subject who was homozygote for ApoE4 were included
into the e4+ group. 22 subjects, matched for age, gender and
education who were e4 negative (e3/e3) were included into the e4-
group. Group characteristics are summarized in Table 1.
ApoE4 Genotyping
APOE genotyping of the two determinating variants rs7412 and
rs429358 was analyzed using pre-designed TaqMan SNP Geno-
typing assays (Applied Biosystems, Foster City, CA). Briefly for
each SNP 20 ml reaction mix contained 15 ng genomic DNA,
unlabeled PCR primers, MGB labeled probes (VIC, 6FAM), 10 ml
of 26TaqMan universal PCR Master Mix (Applied Biosystems,
Foster City, CA). PCR was performed on an ABI 7000 instrument
(Applied Biosystems, Foster City, CA) with the following cycling
programm: 95uC for 15 s, 40 cycles of 95uC for 15 s and 60uC for
60 s. The ABI 7000 genotyping software was used for allelic
discrimination.
Imaging Methods
All MR images were acquired using a Trio 3-T scanner
(Siemens, Erlangen, Germany) with a standard head coil for
radiofrequency transmission and signal reception. Participants
were outfitted with protective earplugs to reduce scanner noise and
a hand-held response device. For T1 weighted structural brain
imaging, an optimized 3D modified driven equilibrium Fourier
transform (3D MDEFT) sequence was used with the following
parameters: acquisition matrix = 2566256, repetition time
(TR) = 7.92 ms, echo time (TE) = 2.48 ms, field of
view = 256 mm, 176 slices, 1.0 mm slice thickness.
A T2-weighted fluid attenuation inversion recovery (FLAIR)
sequence was also acquired to ensure that vascular pathology was
not significant. For all 44 subjects selected from the larger cohort,
no hyperintense white matter lesions were seen in the FLAIR
scans.
High Resolution T1W Structural Image Processing
Images were skull stripped with the Brain Extraction Tool
(BET) from the FSL library. Brain tissue volume, normalised for
subject head size, was estimated with SIENAX [52,53], which is
part of the FSL library. SIENAX starts by extracting brain and
skull images from the single whole-head input data. The brain
Table 1. Demographic and cognitive characteristics of the
sample groups.
APOE4 non-carriers APOE4 carriers
Variable Mean SD Mean SD T-value P-value
n=22 n=22
Age (years) 26.73 4.00 26.86 5.28 5.28 0.92
Gender (m/f) 13/9 13/9 0.76
Education
(years)
16.83 4.46 17.04 4.34 20.15 0.88
MWTB 29.71 3.61 30.27 4.31 20.46 0.65
MWTB IQ 106.70 23.63 114.71 15.34 21.28 0.21
TMT (sec) 22.00 5.85 19.27 3.94 1.81 0.08
WMS SS 19.14 1.98 19.36 2.82 20.31 0.76
LNS 18.73 3.22 17.77 2.65 1.07 0.29
BVMT R 32.67 3.47 32.00 3.61 0.62 0.54
BDI 2 3.23 3.58 2.41 2.92 0.83 0.41
CVLT 66.82 7.96 64.50 9.05 0.90 0.37
Values are mean 6 standard deviation. Significance was set at p,0.05; thus no
significant differences were found between the groups. Values denote mean
and standard deviation or number of subjects. P-values refer to t-tests
(parametric tests) and chi-square tests (for categorial data). Abbreviations:
MWTB: Mehrfachwahl-Wortschatz-Test B, a German Verbal intelligence test;
TMT: trail making test; WMS SS: Spatial Span of the Wechsler Memory Scale;
LNS: Letter Number Sequencing; BVMT R: Brief Visual Memory Test R; BDI 2:
Beck Depression Inventory 2; CVLT: California Verbal Learning Test.
doi:10.1371/journal.pone.0048895.t001
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image is then affine-registered to MNI152 space [54,55] (using the
skull image to determine the registration scaling); this is primarily
in order to obtain the volumetric scaling factor, to be used as a
normalisation for head size. The scaling factor is derived from the
normalisation matrix [53]. Next, tissue-type segmentation with
partial volume estimation is carried out [56] in order to calculate
total volume of brain tissue including separate estimates of
volumes of WM and GM. Both normalised and absolute volumes
of WM and GM were obtained.
FIRST Structural Image Processing
The algorithm FIRST, was applied to separately estimate the
left and right volumes of seven subcortical regions; amygdala,
hippocampus, nucleus accumbens, caudate nucleus, putamen,
pallidum, thalamus and brain stem. FIRST is part of FMRIB’s
Software Library (FSL) and performs both registration and
segmentation of the regions noted above [42]. During registration,
the input data (3D T1 images) are transformed to the MNI
(Montreal Neurological Institute) 152 standard space, by means of
affine transformations based on 12 degrees of freedom. After
subcortical registration, a sub-cortical mask is applied, to locate the
different subcortical structures, followed by segmentation based on
shape models and voxel intensities. Absolute volumes of subcor-
tical structures are calculated, taking into account the transfor-
mations made in the first stage [42]. After registration and
segmentation of all 44 scans, all segmented subcortical regions
were examined visually for problems with registration or
segmentation. No errors were found. An example of subcortical
segmentation of a representative subject is shown in Figure 1.
To obtain neocortical GM volume (NeoCorGM) independent
frorm the deep GM structures of interest, we subtracted the
volumes of the hippocampus and amygdala from the absolute GM
volume as given by SIENAX. Intracranial volume (ICV) was
calculated by adding the volumes of cerebral spinal fluid, total GM
and total WM together. Individual differences in brain size were
corrected by dividing the volumes of specific deep GM structures
by ICV. Thus the following formula was used to compute
normalised volumes of each deep grey matter structure:
total volume of GM structure mm3
 
ICV mm3
 
|1000:
Statistical Analysis
R statistical software, including the lme4 package [57] was used
for all statistical analysis [58]. In the current study, the ‘‘glmer’’
function was used to fit a generalised mixed-effects model using
maximum likelihood (ML). Generalised mixed effects models are
mixed effects models in which both the fixed and random effects
contribute linearly to the response function. Fixed effects influence
the mean of the response, while random effects influence the
variance of the response. The normalised volumes of deep grey
matter structures together with gender were set as fixed effects.
Age was included as a random effect. Thus, the variance that
arises from differences in age among participants is accounted for
in all models. The response variable was set as genotype. The
models are thus assessing the influence of genotype on structural
grey matter volumes.
Two separate models were investigated: a model for the effect of
genotype on the normalised volumes of right hemisphere
structures and a model of the effect of genotype on the normalised
volumes of the left hemisphere structures. The starting model for
the right hemisphere was:
Genotype*Right ThalamuszRight CaudatezRight Putamenz
Right PallidumzRightHippocampuszRight Amygdalaz
Right AccumbenszGenderz 1jAgeð Þ
The starting model for the left hemisphere was:
Genotype*Left ThalamuszLeft CaudatezLeft Putamenz
Left PallidumzLeft HippocampuszLeft Amygdalaz
Left AccumbenszGenderz 1DAgeð Þ
where ‘‘,’’ means ‘‘modelled against’’, ‘‘+’’ means inclusion of an
explanatory variable in the model, and, ‘‘(1|Age)’’ means that Age
is included as a random effect.
All explanatory variables (EVs) were assessed for collinearity.
The volume of the right thalamus was found to be collinear with
the volume of the right hippocampus, the volume of the right
amygdala was also found to be collinear with the right pallidum,
the left thalamus was found to be collinear with the left pallidum
and the left amygdala was found to be collinear with the left
hippocampus. Therefore, residual terms were used for these
volumes, with the right thalamus regressed on the right
hippocampus, the right amygdala regressed on the right pallidum,
the left thalamus regressed on the left pallidum and the left
amgydala regressed on the left hippocampus [59]. When two EVs
are collinear, regression residuals of one variable relative to the
other isolate the unique contribution of each explanatory variable
independent from what is shared between them [60].
We fit the full right and left-side models as described above and
then removed least significant terms from each model separately,
checking for improved fit according to Akaike’s Information
Criterion (AIC) [61,62], until a final model for each side was
obtained [63]. AIC is a function of the likelihood, L, of the data
given the model and the number of variables, in which better
fitting models (i.e. those that match the observed data) have lower
values, after a penalty has been applied for the number of
explanatory variables included in the model. We have previously
employed the AIC tool for successful model selection in an MRI
and structural volume framework [60].
To determine if the final right or left hemisphere model was a
better predictor of genotype, the fit between model and data for
two final models was subsequently compared using the ‘‘anova’’
function in R [63].
Results
Demographic and Cognitive Characteristics
There were no significant differences between the groups in
terms of any of the demographic or psychological measures taken
(Table 1).
Mixed-effect models for the left and right hemisphere to
assess effect of genotype on bilateral grey matter
structural volumes
The volumes of each deep grey matter structure segmented by
FIRST were quantified in terms of both gross volume in mm3
(Table 2) and the volume normalised with total intracranial
volume (Table 3). Normalised volumes were used for the
development of all statistical models. Following model simplifica-
tion, the optimal model for the right hemisphere included the right
hippocampal volume and the right amygdalar volume (Table 4).
Hippocampal Volume in ApoE4 Carriers
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Within the right hemisphere model however, only the right
hippocampal volume was a significant main effect (p = 0.0136).
The optimal model for the left hemisphere contained only the
left hippocampal volume (Table 5).
A comparison of the left and right models indicated that the
right hemisphere model explained the data significantly better
than did the left hemisphere model (p = 0.01) (Table 6).
Regional Shape Change in the Left and Right
Hippocampus
Regional shape changes in the left and right hippocampus were
assessed using vertex analysis within FIRST program. Vertex
analysis creates a 3D mesh displaying the results of vertex analysis
(Fig. 2). The uncorrected F stats are shown for the difference
between ApoE4 carriers and non-carrier. The colour bars indicate
the statistic values; an increase from red to blue represents
progression from lower to higher statistical significance. In the
right hippocampus (Fig. 2, upper panel), blue regions indicate the
areas of most pronounced shape change between ApoE4 carriers
and non-carriers. In the left hippocampus (Fig. 2, lower panel),
there is little significant regional shape change between carriers
and non-carriers. Vertex analysis which corrects for multiple
comparisons however showed no significant region shape changes
between carriers and non-carriers for either the left or the right
hippocampus. This result is expanded upon in the discussion
section.
Discussion
The current results indicate that hippocampal volume is
reduced in healthy young E4 carriers relative to non-carriers with
the right hippocampus being more susceptible to atrophy than the
left hippocampus. Analysis of regional shape changes also
highlighted specific regions of the right hippocampus where
ApoE4 carriers experienced atrophy relative to non-carriers. Such
regional shape changes in ApoE4 carriers were absent in the left
hippocampus. Overall, these results suggest that in ApoE4 carriers,
the right hippocampus is directly vulnerable to atrophy in healthy
young subjects.
Despite the negative effects of ApoE4 genotype on hippocampal
volume, ApoE4 carriers still maintained an equivalent cognitive
performance relative to non-carriers in a range of tests that probed
verbal learning and memory, visual memory, working memory
and attention. This suggests that although early atrophy may be
occurring in ApoE4 carriers in a structure that is known to be
affected in the early stages of AD, actual memory performance is
not yet undermined by this atrophy.
Figure 1. FIRST segmentation of a sample subject. In the middle panel, the putamen is removed to reveal pallidum (bright green).
doi:10.1371/journal.pone.0048895.g001
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The ApoE4 allele is the most well studied risk gene for AD, and
previous work has found that the E4 allele is associated with
increased atrophy of the hippocampus in Alzheimer’s disease [64–
67]. In healthy middle-aged and older non-demented E4 carriers,
lower hippocampal volumes, decreased cortical thickness and
increased rate of hippocampal atrophy relative to E4 non-carriers
have been noted [20,25,35].
In healthy young subjects there are still relatively few studies
which have examined the effect of ApoE genotype on brain
structure and function. In the current study we hypothesised that
hippocampal volume would be reduced in healthy young E4
carriers relative to non-carriers. The rationale for this hypothesis
stems from earlier studies in younger populations, for example in
young children and adolescents, E4 carriers were found to have
thinner entorhinal cortices (EC) relative to E4 non-carriers [19].
Shaw et al. also showed a stepwise increase in cortical thickness in
the EC, with E4 carriers having the thinnest cortex, E2 carriers
having the thickest, and E3 homozygotes having an intermediate
position. Similarly, in healthy young subjects (age ,25 years) E3
homozygotes were found to have hippocampal volumes that were
intermediate between E4 carriers who had the lowest hippocampal
volume and E2 carriers who had the highest hippocampal volumes
[68].
The results from the current study are in general agreement
with these previous works. A generalised mixed-effect model for
the right hemisphere indicated that genotype has an influence on
right hippocampal volume and right amygdalar volume. However,
only the right hippocampus was a significant fixed effect in this
model. For the mixed-effect model of the left hemisphere, only the
left hippocampus remained as a fixed effect following model
simplification. Overall, the results from our mixed-effects models
indicate that ApoE genotype has a significant effect on
hippocampal volume. The volumes of no other structures were
found to be significantly affected by genotype in the current study.
Therefore our results extend the current literature by highlighting
that the vulnerability of the E4 carriers to structural atrophy is
localised to the right hippocampus while there is a general
preservation of all other grey matter structures examined. One
previous study has also noted that there were no differences in
ventricular or hemisphere volumes between healthy young E4
carriers and non-carriers [69]. However, the current results
provide more detailed confirmation of a preservation of deep
grey matter structures outside of the hippocampus in healthy
young E4 carriers. Together, these results support the concept that
E4 status does not have a global effect on the brain regions, but
rather leads to a selective targeting of the hippocampal structure.
There are some earlier studies which failed to find differences in
hippocampal volume between healthy young E4 carriers and non-
Table 2. Absolute volumes of deep grey matter structures in
cubic millimetres for ApoE4+ and ApoE2 groups.
Neg Pos
Mean SD Mean SD Diff.
Left Thalamus 8500 629 8465 782 235
Right Thalamus 8121 670 8098 690 223
Left Amygdala 1415 159 1431 207 16
Right Amygdala 1371 180 1467 217 96
Left Caudate 3966 487 4026 417 60
Right Caudate 4166 427 4207 424 41
Left Putamen 5379 528 5294 369 285
Right Putamen 5383 544 5361 416 222
Left Pallidum 1792 170 1797 113 5
Right Pallidum 1784 182 1828 128 44
Left Hippocampus 4231 403 4019 522 2212
Right Hippocampus 4296 317 3989 604 2307
Left Accumbens 664 126 650 125 214
Right Accumbens 599 100 581 115 218
Brain Stem Ventricle 22353 2480 23146 2988 793
Neg=ApoE42 group. Pos = ApoE4+ group. Diff = difference between Neg and
Pos groups.
doi:10.1371/journal.pone.0048895.t002
Table 3. Volumes of deep grey matter structures for ApoE4+
and ApoE42 groups with volumes normalised by total
intracranial volume.
Neg Pos
Mean SD Mean SD Diff.
Left Thalamus 5.328 0.273 5.267 0.266 20.061
Right Thalamus 5.090 0.298 5.042 0.272 20.048
Left Amygdala 0.888 0.093 0.889 0.092 0.001
Right Amygdala 0.860 0.105 0.914 0.122 0.054
Left Caudate 2.487 0.293 2.513 0.272 0.026
Right Caudate 2.613 0.245 2.624 0.259 0.011
Left Putamen 3.368 0.226 3.303 0.224 20.065
Right Putamen 3.371 0.244 3.342 0.215 20.029
Left Pallidum 1.123 0.083 1.121 0.065 20.002
Right Pallidum 1.117 0.076 1.139 0.064 0.022
Left Hippocampus 2.661 0.288 2.500 0.265 20.161
Right Hippocampus 2.702 0.256 2.486 0.348 20.216
Left Accumbens 0.416 0.075 0.405 0.074 20.011
Right Accumbens 0.375 0.059 0.363 0.072 20.013
Brain Stem Ventricle 14.010 1.360 14.400 1.470 0.390
Neg=ApoE42 group. Pos =ApoE4+ group. Diff. = difference between Neg and
Pos groups. The following formula was used to compute normalized volumes of
each deep grey matter structure:
total volume of GM structure (mm3)/total intracranial volume (mm3)61000.
doi:10.1371/journal.pone.0048895.t003
Table 4. Final, generalised mixed-effect model for genotype
modelled against right hemisphere volumes.
Estimate
Standard
Error z-value p-value
Right Hippocampus 24.155 1.684 22.468 0.0136
Right Amygdala 7.449 3.924 1.898 0.0577
Formula: Genotype , Right Hippocampus + Right Amygdala + (1|Age) where
‘‘,’’ means modelled against, and ‘‘(1|age)’’ means that age is included as a
random effect.
Fixed effects:
A generalised mixed-effect model is run using normalised volumes of right
hemisphere grey matter structures and gender as explanatory variables
together with age as a random effect. Genotype is set as the response variable.
The final model is derived following an iterative model selection procedure that
involves comparing successive models using Akaike’s Information Criterion (see
Methods for detailed description of model selection procedure).
doi:10.1371/journal.pone.0048895.t004
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carriers [26,70]. These discrepancies may stem partly from low
sample sizes and partly from differences in the genotypes being
studied. One previous study [26] examined differences between 10
E2/E3, 10 E3/E3 and 13 E3/E4 subjects and did not find
hippocampal volume differences between these three groups, while
the current study found hippocampal volume differences between
a non-carrier group comprised of 22 E3/E3 subjects and a carrier
group comprised of 21 E3/E3 subjects and one E4/E4 subject.
The larger sample size of the current study, together with the
automated algorithm for segmentation may enable more accurate
detection of subtle volume changes between carriers and non-
carriers. A second study which failed to find hippocampal volume
differences between carrier and non-carrier groups [70] also
employed manual segmentation and included a very heteroge-
neous group of carriers (4 E4/E4 subjects, 12 E3/E4 subjects and
2 E2/E4 subjects) and non-carriers (100 E3/E3 subjects, 2 E2/E2
subjects, 15 E2/E3 subjects). Additionally, the E2 allele variant has
been reported to have a protective effect against AD [71] and
cardiovascular diseases [72], and is also associated with increased
longevity [73]. Thus it is preferable to exclude the E2/E4
genotype from the E4 carrier group. Future studies with larger
cohorts should consider stratifying ApoE groups into more
homogenous subgroups. Considering that the differences in
hippocampal volume between these groups are subtle, more
consistent stratification might help to clear up some of the
discrepancies in the literature.
Volume changes within E4 carriers may be related to changes in
synaptic connections and myelination of the peripheral cortical
neuropil in E4 carriers [19,68]. Within young ApoE4 targeted
replacement (TR) mice also show lower spine density in cortical
layers II/III compared to ApoE2 TR mice [74]. These differences
may be related to increased oxidative insults resulting from
changes in the pro-oxidant/antioxidant balance in E4 carriers
[68,75]. WM tract volume has also been shown to be reduced in
healthy young E4 carriers [76]. These findings suggest that E4
status has a negative effect on both GM and WM structures in
healthy young people. However, the absence of differences in
memory performance between carriers and non-carriers in the
current study and in earlier studies [68] [70,77], suggests that the
brain retains enough reserve capacity at a young age to avoid
decline in cognitive performance despite the structural deficits
outlined above in E4 carriers. Deficits associated with ApoE4 are
more apparent later in life when E4 carriers are more vulnerable
to the cortical thinning observed in aging [78] and AD [79], since
less cortical thinning is necessary in key brain regions in E4
carriers before a critical anatomical threshold is passed, and neural
dysfunctions become clinically evident.
Our finding of a more pronounced main effect of ApoE4
genotype on right hippocampal volume also extends the literature
regarding laterality which has focused to date on older subjects
where greater atrophy in the right hippocampus in E4 carriers has
also been consistently reported [18,37–39,41,80,81] as well as
among AD patients [8,40,66,82]. Interestingly, in healthy controls
a ‘‘normal’’ asymmetry appears to exist with the right hippocam-
pus generally being larger than the left hippocampus; a finding
which has been confirmed in a meta-analysis of 82 studies [36]. In
older subjects, reversal of this typical asymmetry has been
proposed as an indicator of early pathology [37,39–41].
In ApoE4 non-carriers, our results show that mean normalised
volume of the right hippocampus was marginally, though non-
significantly, larger than mean left hippocampal volume. This
finding is consistent with the usual asymmetry reported by the
meta-analysis noted above [36]. Conversely, in ApoE4 carriers
mean normalised volume of the right hippocampus was margin-
ally, though non-significantly, smaller than left hippocampal
volume. Thus, the current results point to a trend towards a
reduction in the ‘‘normal’’ asymmetry of the hippocampus which
has been noted in earlier studies in healthy older and AD cohorts
[36,37,39–41]. Importantly, when comparing both the left and
right hemisphere models, the right hemisphere model was also
found to be a significantly better fit for the data, a finding which
again emphasizes the selective vulnerability of the right hippo-
campus in ApoE4 carriers.
A greater predilection for damage in the right hemisphere has
been noted in fMRI studies. Older E4 carriers have been found to
exhibit more intense activation in parietal, frontal and right medial
temporal lobe regions than non-carriers during the encoding of a
picture learning task [13]. E4 carriers have also been found to
show reduced activation in left hippocampal regions compared to
E3 carriers, which also supports the model of greater compensa-
tory changes occurring in the right hemisphere [13]. These studies
are broadly compatible with the concept of greater right
hemisphere involvement in normal aging as proposed by the
Hemispheric Asymmetry Reduction in Older Adults (HAROLD)
model of Cabeza [83].
Although not all fMRI studies have reported increased
recruitment of right hemisphere activation in E4 carriers [84–
87], differences between studies may be partly accounted for by
the choice of functional tasks employed. A spatial context memory
task which involves the right hemisphere in visuospatial processing
was used in the study which found the greatest amount of
compensatory right hemisphere activation [88]. The lack of a right
Table 5. Final, generalised mixed-effect model for genotype
modelled against left hemisphere volumes.
Estimate
Standard
Error z-value p-value
Left Hippocampus 22.293 1.289 21.779 0.0753
Formula: Genotype , Left Hippocampus + (1|Age).
Fixed effects:
A generalised mixed-effect model is run using normalised volumes of left
hemisphere grey matter structures and gender as explanatory variables
together with age as a random effect. Genotype is set as the response variable.
The final model is derived following an iterative model selection procedure that
involves comparing successive models using Akaike’s Information Criterion (see
Methods for detailed description of model selection procedure).
doi:10.1371/journal.pone.0048895.t005
Table 6. Comparison of left and right hemisphere models.
Df AIC BIC logLik p-value
Left Hem 3 63.202 68.555 228.601
Right Hem 4 58.582 65.719 225.291 0.01008
Models:
Left hemisphere: Genotype , Left Hippocampus + (1|Age).
Right hemisphere: Genotype , Right Hippocampus + Right Amygdala +
(1|Age).
The AIC value of the right hemisphere model is lower than that of the left
hemisphere model. The right hemisphere model is also indicated to be a
significantly better fit of the data than the left hemisphere model. See Methods
for a detailed description of model comparison procedure and AIC calculation.
Abbreviations: Hem, Hemisphere; Df, Degrees of freedom; AIC, Akaike’s
Information Criterion Score; BIC, Bayesian Information Criterion; LogLik, Log-
Likelihood.
doi:10.1371/journal.pone.0048895.t006
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hemisphere effect in other studies [84–87] may be related to tasks
with an emphasis on language that would activate the left rather
than the right hemisphere [33].
Findings of increased functional connectivity between medial
temporal lobe (MTL) regions and other regions known to be
affected by AD (e.g. posterior cingulate) in young E4 carriers also
suggest that ApoE begins to be expressed in AD-associated brain
regions long before cognitive decline [29]. Filbey et al. reported
that young E4 carriers showed more medial frontal, cingulate and
MTL activity compared to non-carriers in a working memory task
[27]. In general agreement with this, other work has found that E4
carriers have more default mode network (DMN) connectivity and
more hippocampal activation during a memory encoding task
than non-carriers [28]. However, a study by Mondadori et al. [26]
found that E4 carriers exhibited less neural activity in bilateral
MTL and left frontal regions during the encoding and retrieval
portions of an episodic memory task than performance-matched
non-carriers. This was attributed to enhanced neural efficiency of
memory networks in young adult E4 carriers which offers some
support for a model of antagonistic pleiotrophy. Although
hippocampal volume is reduced in the current cohort of healthy
young E4 carriers, no cognitive differences were noted between
carriers and non-carriers. Whether or not this equivalence of
performance is achieved through extra compensation in the E4
Figure 2. Regional shape changes in the left and right hippocampus using vertex analysis. Results show uncorrected F stats for the
difference between ApoE4 carriers and non-carrier. The colour bar indicates the statistic values; an increase from red to blue is going from a lower to
higher statistical significance. The right hippocampus is shown in the upper panel with the most significant differences between ApoE4 carriers and
non-carriers shown in blue. The lower panel shows the left hippocampus. Note that there are no blue regions indicated on the lower panel, indicating
that significant shape change is more pronounced in the right hippocampus.
doi:10.1371/journal.pone.0048895.g002
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carriers is not possible to say. It may be the case that cognitive
deficits only become evident in E4 carriers when the risk allele is
compounded by an additional risk factor such as AD history in the
family [89].
In old age, the majority of studies note that E4 carriers have
greater rates of cognitive decline compared with non-carriers
[24,90]. It could be hypothesized that structural changes occurring
in healthy twenty year olds as a result of possession of the E4 allele,
may not affect cognitive function at this early stage but may lay the
ground work for faster cognitive decline in older age. Although
there are exceptions, most studies have noted that E4 carriers
performed worse in tasks of verbal and visual episodic memory
compared with non-carriers. Also, studies have noted that those
with two E4 alleles experienced more memory decline before those
with only one E4 allele [91].
A limitation of the current study is that we do not know how the
subjects progress over time. A longitudinal study which would
follow healthy young carriers and non-carriers of the E4 allele over
a period of ten or more years is warranted. Although there may be
some limitations with regards to the FIRST algorithm, each
subject’s segmentations were carefully examined and found to be
of good quality. The FIRST algorithm may offer some advantages
over voxel-based morphometry (VBM) as VBM is prone to
registration artefacts in deep GM structures [92]. FIRST is also
more objective than manual segmentation methods which may not
be sufficiently sensitive to detect subtle regional changes and
localised volume loss. The algorithm proceeds with segmentation
based on the intensity values of voxels and avoids the biases that
arise when a researcher must visually judge contrasts in order to
delineate boundaries during manual segmentation.
Overall, our results suggest that in the E4 carrier group, even
among healthy subjects as young as 25 years of age, there are
subtle structural changes in the hippocampus leading to volume
reduction which are significant in the right hemisphere. Our
results lend support to a growing body of evidence that indicates
that the right hemisphere may have a greater predilection for
damage in the very early stages of neurodegeneration. Our results
also suggest that E4 carriers that exhibit volume reduction in the
right hippocampus may be at greater risk of neurodgeneration in
later life and that the structural deficits found in young carriers
may not be clinically manifest until much later time points.
However, future studies with larger sample sizes, as well as
longitudinal studies will be needed to confirm this.
Acknowledgments
We thank Ce´line Bourdon and Felix Geser for comments, discussion and
assistance relating to the manuscript.
Author Contributions
Conceived and designed the experiments: LO SM DP HH. Performed the
experiments: LO SM MS JM. Analyzed the data: LO FL CT. Contributed
reagents/materials/analysis tools: FL DR CT. Wrote the paper: LO.
References
1. Beffert U, Stolt PC, Herz J (2004) Functions of lipoprotein receptors in neurons.
J Lipid Res. 45: 403–409. doi:10.1194/jlr.R300017-JLR200
2. Beffert U, Nematollah Farsian F, Masiulis I, Hammer RE, Yoon SO, et al.
(2006) ApoE receptor 2 controls neuronal survival in the adult brain. Curr Biol.
16: 2446–2452. doi:10.1016/j.cub.2006.10.029
3. Finch CE, Sapolsky RM (1999) The evolution of Alzheimer disease, the
reproductive schedule, and apoE isoforms. Neurobiol Aging 20: 407–428.
4. Verghese PB, Castellano JM, Holtzman DM (2011) Apolipoprotein E in
Alzheimer’s disease and other neurological disorders. The Lancet Neurology 10:
241–252. doi:10.1016/S1474-4422(10)70325-2
5. Zannis VI, Breslow JL, Utermann G, Mahley RW, Weisgraber KH, et al. (1982)
Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes.
J Lipid Res. 23: 911–914.
6. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, et al.
(1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s
disease in late onset families. Science 261: 921–923.
7. Okuizumi K, Onodera O, Tanaka H, Kobayashi H, Tsuji S, et al. (1994) ApoE-
epsilon 4 and early-onset Alzheimer’s. Nat Genet. 7: 10–11. doi:10.1038/
ng0594-10b
8. Lehtovirta M, Laakso MP, Soininen H, Helisalmi S, Mannermaa A, et al. (1995)
Volumes of hippocampus, amygdala and frontal lobe in Alzheimer patients with
different apolipoprotein E genotypes. Neuroscience 67: 65–72.
9. Filippini N, Rao A, Wetten S, Gibson RA, Borrie M, et al. (2009) Anatomically-
distinct genetic associations of APOE epsilon4 allele load with regional cortical
atrophy in Alzheimer’s disease. Neuroimage 44: 724–728. doi:10.1016/
j.neuroimage.2008.10.003
10. Bookheimer SY, Strojwas MH, Cohen MS, Saunders AM, Pericak-Vance MA,
et al. (2000) Patterns of brain activation in people at risk for Alzheimer’s disease.
N Engl J Med 343: 450–456. doi:10.1056/NEJM200008173430701
11. Small GW, Ercoli LM, Silverman DH, Huang SC, Komo S, et al. (2000)
Cerebral metabolic and cognitive decline in persons at genetic risk for
Alzheimer’s disease. Proc Natl Acad Sci. U.S.A 97: 6037–6042. doi:10.1073/
pnas.090106797
12. Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, et al. (2004)
Functional brain abnormalities in young adults at genetic risk for late-onset
Alzheimer’s dementia. Proc Natl Acad Sci USA 101: 284–289. doi:10.1073/
pnas.2635903100
13. Bondi MW, Houston WS, Eyler LT, Brown GG (2005) fMRI evidence of
compensatory mechanisms in older adults at genetic risk for Alzheimer disease.
Neurology 64: 501–508. doi:10.1212/01.WNL.0000150885.00929.7E
14. Wishart HA, Saykin AJ, McAllister TW, Rabin LA, McDonald BC, et al. (2006)
Regional brain atrophy in cognitively intact adults with a single APOE epsilon4
allele. Neurology 67: 1221–1224. doi:10.1212/01.wnl.0000238079.00472.3a
15. Frisoni GB, Laakso MP, Beltramello A, Geroldi C, Bianchetti A, et al. (1999)
Hippocampal and entorhinal cortex atrophy in frontotemporal dementia and
Alzheimer’s disease. Neurology 52: 91–100.
16. Du A-T, Schuff N, Chao LL, Kornak J, Jagust WJ, et al. (2006) Age effects on
atrophy rates of entorhinal cortex and hippocampus. Neurobiol Aging 27: 733–
740. doi:10.1016/j.neurobiolaging.2005.03.021
17. Barboriak DP, Doraiswamy PM, Krishnan KR, Vidyarthi S, Sylvester J, et al.
(2000) Hippocampal sulcal cavities on MRI: relationship to age and
apolipoprotein E genotype. Neurology 54: 2150–2153.
18. den Heijer T, Oudkerk M, Launer LJ, van Duijn CM, Hofman A, et al. (2002)
Hippocampal, amygdalar, and global brain atrophy in different apolipoprotein
E genotypes. Neurology 59: 746–748.
19. Shaw P, Lerch JP, Pruessner JC, Taylor KN, Rose AB, et al. (2007) Cortical
morphology in children and adolescents with different apolipoprotein E gene
polymorphisms: an observational study. The Lancet Neurology 6: 494–500.
doi:10.1016/S1474-4422(07)70106-0
20. Burggren AC, Zeineh MM, Ekstrom AD, Braskie MN, Thompson PM, et al.
(2008) Reduced cortical thickness in hippocampal subregions among cognitively
normal apolipoprotein E e4 carriers. Neuroimage 41: 1177–1183. doi:10.1016/
j.neuroimage.2008.03.039
21. Schmidt H, Schmidt R, Fazekas F, Semmler J, Kapeller P, et al. (1996)
Apolipoprotein E e4 allele in the normal elderly: neuropsychologic and brain
MRI correlates. Clin Genet. 50: 293–299.
22. Reiman EM, Uecker A, Caselli RJ, Lewis S, Bandy D, et al. (1998)
Hippocampal volumes in cognitively normal persons at genetic risk for
Alzheimer’s disease. Ann Neurol. 44: 288–291. doi:10.1002/ana.410440226
23. Cherbuin N, Anstey KJ, Sachdev PS, Maller JJ, Meslin C, et al. (2008) Total and
regional gray matter volume is not related to APOE*E4 status in a community
sample of middle-aged individuals. J Gerontol A Biol Sci Med Sci. 63: 501–504.
24. Cosentino S, Scarmeas N, Helzner E, Glymour MM, Brandt J, et al. (2008)
APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease.
Neurology 70: 1842–1849. doi:10.1212/01.wnl.0000304038.37421.cc
25. Lind J, Persson J, Ingvar M, Larsson A, Cruts M, et al. (2006) Reduced
functional brain activity response in cognitively intact apolipoprotein E epsilon4
carriers. Brain 129: 1240–1248. doi:10.1093/brain/awl054
26. Mondadori CRA, de Quervain DJ-F, Buchmann A, Mustovic H, Wollmer MA,
et al. (2007) Better memory and neural efficiency in young apolipoprotein E
epsilon4 carriers. Cereb Cortex 17: 1934–1947. doi:10.1093/cercor/bhl103
27. Filbey FM, Slack KJ, Sunderland TP, Cohen RM (2006) Functional magnetic
resonance imaging and magnetoencephalography differences associated with
APOEepsilon4 in young healthy adults. Neuroreport 17: 1585–1590.
doi:10.1097/01.wnr.0000234745.27571.d1
28. Filippini N, MacIntosh BJ, Hough MG, Goodwin GM, Frisoni GB, et al. (2009)
Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele.
Proc Natl Acad Sci USA 106: 7209–7214. doi:10.1073/pnas.0811879106
Hippocampal Volume in ApoE4 Carriers
PLOS ONE | www.plosone.org 8 November 2012 | Volume 7 | Issue 11 | e48895
29. Dennis NA, Browndyke JN, Stokes J, Need A, Burke JR, et al. (2010) Temporal
lobe functional activity and connectivity in young adult APOE varepsilon4
carriers. Alzheimers Dement 6: 303–311. doi:10.1016/j.jalz.2009.07.003
30. Liu F, Pardo LM, Schuur M, Sanchez-Juan P, Isaacs A, et al. (2010) The
apolipoprotein E gene and its age-specific effects on cognitive function.
Neurobiol Aging 31: 1831–1833. doi:10.1016/j.neurobiolaging.2008.09.015
31. Marchant NL, King SL, Tabet N, Rusted JM (2010) Positive Effects of
Cholinergic Stimulation Favor Young APOE e4 Carriers. Neuropsychophar-
macology 35: 1090–1096. doi:10.1038/npp.2009.214
32. Han SD, Bondi MW (2008) Revision of the apolipoprotein E compensatory
mechanism recruitment hypothesis. Alzheimers Dement 4: 251–254.
doi:10.1016/j.jalz.2008.02.006
33. Tuminello ER, Han SD (2011) The apolipoprotein e antagonistic pleiotropy
hypothesis: review and recommendations. Int J Alzheimers Dis 2011: 726197.
doi:10.4061/2011/726197
34. Mueller SG, Weiner MW (2009) Selective effect of age, Apo e4, and Alzheimer’s
disease on hippocampal subfields. Hippocampus 19: 558–564. doi:10.1002/
hipo.20614
35. Jak AJ, Houston WS, Nagel BJ, Corey-Bloom J, Bondi MW (2007) Differential
cross-sectional and longitudinal impact of APOE genotype on hippocampal
volumes in nondemented older adults. Dement Geriatr Cogn Disord 23: 382–
389. doi:10.1159/000101340
36. Pedraza O, Bowers D, Gilmore R (2004) Asymmetry of the hippocampus and
amygdala in MRI volumetric measurements of normal adults. J Int Neurop-
sychol Soc 10: 664–678. doi:10.1017/S1355617704105080
37. Soininen H, Partanen K, Pitka¨nen A, Hallikainen M, Ha¨nninen T, et al. (1995)
Decreased hippocampal volume asymmetry on MRIs in nondemented elderly
subjects carrying the apolipoprotein E epsilon 4 allele. Neurology 45: 391–392.
38. Tohgi H, Takahashi S, Kato E, Homma A, Niina R, et al. (1997) Reduced size
of right hippocampus in 39- to 80-year-old normal subjects carrying the
apolipoprotein E epsilon4 allele. Neurosci Lett. 236: 21–24.
39. Geroldi C, Laakso MP, DeCarli C, Beltramello A, Bianchetti A, et al. (2000)
Apolipoprotein E genotype and hippocampal asymmetry in Alzheimer’s disease:
a volumetric MRI study. J Neurol Neurosurg Psychiatr. 68: 93–96.
40. Barnes LL, Wilson RS, Bienias JL, Schneider JA, Evans DA, et al. (2005) Sex
differences in the clinical manifestations of Alzheimer disease pathology. Arch
Gen Psychiatry 62: 685–691. doi:10.1001/archpsyc.62.6.685
41. Lu PH, Thompson PM, Leow A, Lee GJ, Lee A, et al. (2011) Apolipoprotein E
genotype is associated with temporal and hippocampal atrophy rates in healthy
elderly adults: a tensor-based morphometry study. J Alzheimers Dis. 23: 433–
442. doi:10.3233/JAD-2010-101398
42. Patenaude B, Smith SM, Kennedy DN, Jenkinson M (2011) A Bayesian model
of shape and appearance for subcortical brain segmentation. Neuroimage 56:
907–922. doi:10.1016/j.neuroimage.2011.02.046
43. Oldfield RC (1971) The assessment and analysis of handedness: the Edinburgh
inventory. Neuropsychologia 9: 97–113.
44. Delis DC, Kramer JH, Kaplan E, Ober BA (1987) California Verbal Learning
Test: Adult version. San Antonio, Texas: Psychological Corporation.
45. Niemann H, Sturm W, Thone-Otto AIT, Willmes K (2008) California Verbal
Learning Test (CVLT). Deutsche adaptation. Frankfurt: Pearson Clinical &
Talent Assessment.
46. Benedict R (1997) BriefVisuospatial Memory Test-Revised professional manual.
Odessa, FL: Psychological Assessment Resources, Inc.
47. Gold JM, Carpenter C, Randolph C, Goldberg TE, Weinberger DR (1997)
Auditory working memory and Wisconsin Card Sorting Test performance in
schizophrenia. Arch Gen Psychiatry 54: 159–165.
48. Wechsler D (1997) WMS-III administration and scoring manual. San Antonio:
The Psychological Corporation.
49. Lehrl S (1995) Mehrfachwahl-Wortschatz-Test (MWT-B). Erlangen: Straube.
50. Beck AT, Steer RA, Brown GK (1996) Beck Depression Inventory. Second ed.
San Antonio, Texas: The Psychological Corporation.
51. Hautzinger M, Keller F, Kuhner C (2006) ‘‘BDI II’’ Beck Depressions-Inventar.
Second ed. Frankfurt: Harcourt Test Services.
52. Smith SM, De Stefano N, Jenkinson M, Matthews PM (2001) Normalized
accurate measurement of longitudinal brain change. J Comput Assist Tomogr
25: 466–475.
53. Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM, et al. (2002)
Accurate, robust, and automated longitudinal and cross-sectional brain change
analysis. Neuroimage 17: 479–489.
54. Jenkinson M, Smith S (2001) A global optimisation method for robust affine
registration of brain images. Med Image Anal 5: 143–156.
55. Jenkinson M, Bannister P, Brady M, Smith S (2002) Improved optimization for
the robust and accurate linear registration and motion correction of brain
images. Neuroimage 17: 825–841.
56. Zhang Y, Brady M, Smith S (2001) Segmentation of brain MR images through a
hidden Markov random field model and the expectation-maximization
algorithm. IEEE Trans Med Imaging 20: 45–57. doi:10.1109/42.906424
57. Bates D, Maechler M, Bolker B (2011) lme4: Linear Mixed-Effects Models Using
S4 Classes. Available: http://CRAN.R-project.org/package = lme4.
58. R Development Core Team (2010) R: A Language and Environment for
Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing.
Available: http://www.R-project.org.
59. Graham MH (2003) Confronting multicollinearity in ecologocial multiple
regression. Ecology 84: 2809–2815. doi:10.1890/02-3114
60. O’Dwyer L, Lamberton F, Bokde ALW, Ewers M, Faluyi YO, et al. (2011)
Using Diffusion Tensor Imaging and Mixed-Effects Models to Investigate
Primary and Secondary White Matter Degeneration in Alzheimer’s Disease and
Mild Cognitive Impairment. J Alzheimers Dis. Available: http://www.ncbi.nlm.
nih.gov/pubmed/21694456. Accessed 2011 Jun 25.
61. Anderson DR, Burnham KP (2002) Model selection and multimodel inference: a
practical information-theoretic approach. 2nd ed. New York, New York, USA:
Springer-Verlag.
62. Akaike H (1979) A Bayesian extension of the minimum AIC procedure of
autoregressive model fitting. Biometrika 66: 237–242. doi:10.1093/biomet/
66.2.237
63. Crawley MJ (2007) The R Book. Available: http://onlinelibrary.wiley.com/
book/10.1002/9780470515075. Accessed 2012 Aug 31.
64. Lehtovirta M, Soininen H, Laakso MP, Partanen K, Helisalmi S, et al. (1996)
SPECT and MRI analysis in Alzheimer’s disease: relation to apolipoprotein E
epsilon 4 allele. J Neurol Neurosurg Psychiatr. 60: 644–649.
65. Geroldi C, Pihlajama¨ki M, Laakso MP, DeCarli C, Beltramello A, et al. (1999)
APOE-epsilon4 is associated with less frontal and more medial temporal lobe
atrophy in AD. Neurology 53: 1825–1832.
66. Hashimoto M, Yasuda M, Tanimukai S, Matsui M, Hirono N, et al. (2001)
Apolipoprotein E epsilon 4 and the pattern of regional brain atrophy in
Alzheimer’s disease. Neurology 57: 1461–1466.
67. Mori E, Lee K, Yasuda M, Hashimoto M, Kazui H, et al. (2002) Accelerated
hippocampal atrophy in Alzheimer’s disease with apolipoprotein E epsilon4
allele. Ann Neurol. 51: 209–214.
68. Alexopoulos P, Richter-Schmidinger T, Horn M, Maus S, Reichel M, et al.
(2011) Hippocampal Volume Differences Between Healthy Young Apolipopro-
tein E e2 and e4 Carriers. Journal of Alzheimer’s Disease 26: 207–210.
doi:10.3233/JAD-2011-110356
69. Sidiropoulos C, Jafari-Khouzani K, Soltanian-Zadeh H, Mitsias P, Alexopoulos
P, et al. (2011) Influence of brain-derived neurotrophic factor and apolipoprotein
E genetic variants on hemispheric and lateral ventricular volume of young
healthy adults. Acta Neuropsychiatr 23: 132–138. doi:10.1111/j.1601-
5215.2011.00546.x
70. Richter-Schmidinger T, Alexopoulos P, Horn M, Maus S, Reichel M, et al.
(2011) Influence of brain-derived neurotrophic-factor and apolipoprotein E
genetic variants on hippocampal volume and memory performance in healthy
young adults. J Neural Transm 118: 249–257. doi:10.1007/s00702-010-0539-8
71. Benjamin R, Leake A, Edwardson JA, McKeith IG, Ince PG, et al. (1994)
Apolipoprotein E genes in Lewy body and Parkinson’s disease. Lancet 343:
1565.
72. Wilson PW, Myers RH, Larson MG, Ordovas JM, Wolf PA, et al. (1994)
Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The
Framingham Offspring Study. JAMA 272: 1666–1671.
73. Scha¨chter F, Faure-Delanef L, Gue´not F, Rouger H, Froguel P, et al. (1994)
Genetic associations with human longevity at the APOE and ACE loci. Nat
Genet. 6: 29–32. doi:10.1038/ng0194-29
74. Dumanis SB, Tesoriero JA, Babus LW, Nguyen MT, Trotter JH, et al. (2009)
ApoE4 decreases spine density and dendritic complexity in cortical neurons in
vivo. J Neurosci. 29: 15317–15322. doi:10.1523/JNEUROSCI.4026-09.2009
75. Kharrazi H, Vaisi-Raygani A, Rahimi Z, Tavilani H, Aminian M, et al. (2008)
Association between enzymatic and non-enzymatic antioxidant defense
mechanism with apolipoprotein E genotypes in Alzheimer disease. Clin
Biochem. 41: 932–936. doi:10.1016/j.clinbiochem.2008.05.001
76. O’Dwyer L, Lamberton F, Matura S, Scheibe M, Miller J, et al. (2012) White
Matter Differences between Healthy Young ApoE4 Carriers and Non-Carriers
Identified with Tractography and Support Vector Machines. PLoS ONE 7:
e36024. doi:10.1371/journal.pone.0036024
77. Scarmeas N, Habeck CG, Hilton J, Anderson KE, Flynn J, et al. (2005) APOE
related alterations in cerebral activation even at college age. J Neurol Neurosurg
Psychiatr. 76: 1440–1444. doi:10.1136/jnnp.2004.053645
78. Hedden T, Gabrieli JDE (2004) Insights into the ageing mind: a view from
cognitive neuroscience. Nat Rev Neurosci. 5: 87–96. doi:10.1038/nrn1323
79. Minati L, Edginton T, Bruzzone MG, Giaccone G (2009) Current concepts in
Alzheimer’s disease: a multidisciplinary review. Am J Alzheimers Dis Other
Demen 24: 95–121. doi:10.1177/1533317508328602
80. Plassman BL, Welsh-Bohmer KA, Bigler ED, Johnson SC, Anderson CV, et al.
(1997) Apolipoprotein E epsilon 4 allele and hippocampal volume in twins with
normal cognition. Neurology 48: 985–989.
81. Lemaıˆtre H, Crivello F, Dufouil C, Grassiot B, Tzourio C, et al. (2005) No
epsilon4 gene dose effect on hippocampal atrophy in a large MRI database of
healthy elderly subjects. Neuroimage 24: 1205–1213. doi:10.1016/j.neuro-
image.2004.10.016
82. Bigler ED, Lowry CM, Anderson CV, Johnson SC, Terry J, et al. (2000)
Dementia, quantitative neuroimaging, and apolipoprotein E genotype. AJNR
Am J Neuroradiol 21: 1857–1868.
83. Cabeza R (2002) Hemispheric asymmetry reduction in older adults: the
HAROLD model. Psychol Aging 17: 85–100.
84. Bartre´s-Faz D, Serra-Grabulosa JM, Sun FT, Sole´-Padulle´s C, Rami L, et al.
(2008) Functional connectivity of the hippocampus in elderly with mild memory
dysfunction carrying the APOE epsilon4 allele. Neurobiol Aging 29: 1644–1653.
doi:10.1016/j.neurobiolaging.2007.04.021
85. Trivedi MA, Schmitz TW, Ries ML, Hess TM, Fitzgerald ME, et al. (2008)
fMRI activation during episodic encoding and metacognitive appraisal across
Hippocampal Volume in ApoE4 Carriers
PLOS ONE | www.plosone.org 9 November 2012 | Volume 7 | Issue 11 | e48895
the lifespan: risk factors for Alzheimer’s disease. Neuropsychologia 46: 1667–
1678. doi:10.1016/j.neuropsychologia.2007.11.035
86. Woodard JL, Seidenberg M, Nielson KA, Antuono P, Guidotti L, et al. (2009)
Semantic memory activation in amnestic mild cognitive impairment. Brain 132:
2068–2078. doi:10.1093/brain/awp157
87. Filbey FM, Chen G, Sunderland T, Cohen RM (2010) Failing compensatory
mechanisms during working memory in older apolipoprotein E-epsilon4 healthy
adults. Brain Imaging Behav 4: 177–188. doi:10.1007/s11682-010-9097-9
88. Kukolja J, Thiel CM, Eggermann T, Zerres K, Fink GR (2010) Medial temporal
lobe dysfunction during encoding and retrieval of episodic memory in non-
demented APOE epsilon4 carriers. Neuroscience 168: 487–497. doi:10.1016/
j.neuroscience.2010.03.044
89. Seidenberg M, Guidotti L, Nielson KA, Woodard JL, Durgerian S, et al. (2009)
Semantic memory activation in individuals at risk for developing Alzheimer
disease. Neurology 73: 612–620. doi:10.1212/WNL.0b013e3181b389ad
90. Schiepers OJG, Harris SE, Gow AJ, Pattie A, Brett CE, et al. (2011) APOE E4
status predicts age-related cognitive decline in the ninth decade: longitudinal
follow-up of the Lothian Birth Cohort 1921. Mol Psychiatry. Available: http://
www.ncbi.nlm.nih.gov/pubmed/21263443. Accessed 2 Feb 2012.
91. Caselli RJ, Dueck AC, Osborne D, Sabbagh MN, Connor DJ, et al. (2009)
Longitudinal Growth Modeling of Cognitive Aging and the APOE e4 Effect.
N Engl J Med 361: 255–263. doi:10.1056/NEJMoa0809437
92. Frisoni GB, Whitwell JL (2008) How fast will it go, doc? New tools for an old
question from patients with Alzheimer disease. Neurology 70: 2194–2195.
doi:10.1212/01.wnl.0000313844.18381.a9
Hippocampal Volume in ApoE4 Carriers
PLOS ONE | www.plosone.org 10 November 2012 | Volume 7 | Issue 11 | e48895
